Skip to main content

Table 1 Demographic characteristics of patients, risk factors and outcome

From: A comparison of blood stream infections with extended spectrum beta-lactamase-producing and non-producing Klebsiella pneumoniae in pediatric patients

 

ESBL (+)

n = 69

ESBL (−)

n = 42

p

Gendera

  

0.99

 Male

37(63.8)

21(36.2)

 

 Female

24(61.5)

15(38.5)

 

Age (months)b

4.9(1.7–26)

16.4(3.1–69.1)

0.04

Total length of hospitalization (days)b

56(32–89)

34(21–71)

0.03

Length of stay in hospital before infection (days)b

33(11.5–59.5)

11.5(0–26)

0.001

Duration of treatment for infection (days)b

16(11–21.5)

17(12–23)

0.66

Underlying medical condition/diseasea

  

NA

 Hematologic malignancy

7(11.4)

8(22.2)

 

 Oncologic malignancy

6(9.8)

10(27.2)

 

 Congenital heart anomalies

8(13.1)

4(11.1)

 

 Primary immunodeficiencies

2(3.2)

1(2.7)

 

 Neurologic/Metabolic disease

10(16.3)

4(11.1)

 

 Gastrointestinal disease

9(14.7)

6(16.6)

 Prematurity

6(9.8)

1(2.7)

 

 Others

13(21.3)

2(5.5)

 

Mechanical ventilationa

31(81.6)

7(18.4)

0.005

Presence of central venous cathetera

34(60.7)

22(39.3)

0.90

Prior surgerya

33(66)

17(34)

0.57

Polymicrobial bacteremiaa

6(42.9)

8(57.1)

0.19

Prior chemotherapy associated neutropeniaa

15(46.9)

17(53.1)

0.058

Prior K. pneumoniae colonizationa

7

5

NA

Prior antibiotic usea

 Broad spectrum cephalosporins

21(75)

7(25)

0.16

 Fluoroquinolones

15(75)

5(25)

0.29

 Carbapenems

25(61)

16(39)

1.0

 Aminoglycosides

47(77)

14(23)

0.001

 Glycopeptides

35(71.4)

14(28.6)

0.11

Use of more than one of the antibiotics studieda

52(75.4)

17(24.6)

0.001

Outcomea

 Crude Mortality

20 (29)

7 (16.7)

0.21

 30 day mortality

17(24.6)

5 (11.9)

0.16

 60 day mortality

19 (27.5)

7(16.7)

0.28

 Response at day 6

42(58.3)

30(41.7)

0.44

 Relapse

5(4.5)

4(3.6)

0.67

  1. anumber, %; bMedian, IQR: Interquartile range
  2. ESBL (+): ESBL –producing isolates, ESBL (−): ESBL –non-producing isolates